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Negative symptoms of schizophrenia are normally grouped into a single category. However, the diversity
of such symptoms suggests that they are actually made up of more than one dimension. The DSM-V
proposes two negative symptom domains, namely expressive deﬁcits and avolition/asociality. We
investigated whether the negative symptoms do indeed have two dimensions. An exploratory factor
analysis was carried out based on interviews with the PANSS (664 patients). We restricted our analysis to
items that had been described as negative symptoms in previous factor analyses. The symptom structure
was then tested for stability by performing a conﬁrmatory factor analysis on PANSS interviews from a
separate cohort (2172 patients). Exploratory factor analysis yielded a two-factor structure of negative
symptoms. The ﬁrst factor consisted of PANSS items Flat affect, Poor rapport, Lack of spontaneity,
Mannerisms and posturing, Motor retardation, and Avolition. The second factor consisted of Emotional
withdrawal, Passive/apathetic social withdrawal, and Active social avoidance. The ﬁrst factor could be
related to expressive deﬁcits, reﬂecting a loss of initiative, and the second factor to social amotivation,
related to community interaction. This factor structure supports the DSM-V classiﬁcation and may be
relevant for pathophysiology and treatment of schizophrenia and other psychotic disorders.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The symptoms of schizophrenia and other psychotic disorders
are often categorized into three main domains: positive symptoms,
negative symptoms, and cognitive impairments (American
Psychiatric Association, 2000; Mueser and McGurk, 2004). Nega-
tive symptoms have been deﬁned as an absence of normal behaviors,Mental Health, Hereweg 80,
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sevier OA license.including ﬂattened emotional response, poverty of speech, lack of
initiative, lack of pleasure and social withdrawal (Andreasen and
Flaum, 1991). They are difﬁcult to treat and are an important pre-
dictor for poor social outcome in schizophrenia (Pinkham et al.,
2003).
The current DSM-IV considers negative symptoms as one
dimension. However, instruments like the Scale for Assessment of
Negative Symptoms (SANS) or the Positive and Negative Syndrome
Scale (PANSS) show considerable heterogeneity in items measuring
negative symptoms (Andreasen, 1983; Kay et al., 1987). This wide
range of symptoms, hitherto classiﬁed as one group, may in fact
reﬂect different subgroups, with each a different neural, social, or
psychological etiology (Keefe et al., 1992). The new DSM-V pro-
poses a two-subdomain model of negative symptoms, with one
domain related to expressive deﬁcits including affective, linguistic
E. Liemburg et al. / Journal of Psychiatric Research 47 (2013) 718e725 719and paralinguistic expressions, and the second domain related to
avolition for social activities (Kirkpatrick and Fischer, 2006;
Messinger et al., 2011). Such a classiﬁcation with two subgroups
could have important implications for research, diagnostics and
treatment (Blanchard and Cohen, 2006; Messinger et al., 2011).
Negative symptoms have always been the ‘pièce de résistance’
in treatment. Recently some evidence is emerging that treatment
with modaﬁnil may have beneﬁcial effects on negative symptoms
(Arbabi et al., 2011), mainly restricted to the anhedonia-asociality
item of the SANS (Bobo et al., 2011). Cognitive behavioral therapy
is reported to be effective in improving motivation, apathy and
social participation (Grant et al., 2011). Thus, these treatments may
address different biological and psychological issues of the group of
negative symptoms. Instruments that reliably distinguish these two
distinct subgroups of symptoms could be supportive for the
research into treatment strategies aimed at negative symptoms.
One way to investigate whether negative symptoms comprise
more than one symptom domain is to assess the correlational
structure of the measures by factor analysis (Blanchard and Cohen,
2006; Stevens, 1996; Tabachnik and Fidell, 2007). Factor analyses
have already established that negative symptoms comprise a
separate domain within the full symptom range seen in schizo-
phrenia and related psychotic disorders (Blanchard and Cohen,
2006; Van der Gaag et al., 2006a,b). However, the concept of
negative symptoms is still heterogeneous, and previous studies
with factor analysis have shown that there may be two (or three)
subdomains (Blanchard and Cohen, 2006; Kirkpatrick and Fischer,
2006; Kirkpatrick et al., 2006; Peralta and Cuesta, 1995).
Although negative symptoms often constitute one factor in
factor analysis of the whole PANSS (Van der Gaag et al., 2006a,b),
this negative symptom factor appears to be unstable or sometimes
even split (Blanchard and Cohen, 2006; Lindström and Von
Knorring, 1993; Van den Oord et al., 2006). In factor analysis the
number of factors is often predeﬁned or based on variance mea-
sures. When the number of factors is set too low, this could force all
negative symptoms in one factor, while they should actually
constitute multiple factors (Blanchard and Cohen, 2006).
The aim of this study is to increase generalizability of earlier
ﬁndings reporting on two sub-domains of negative symptoms. So
far, most studies on the structure of negative symptoms have used
the Scale for Assessment of Negative Symptoms (SANS) (Andreasen,
1983). Since inferences based on one symptom scale are limited
(Blanchard and Cohen, 2006; Horan et al., 2006), replication with
the Positive and Negative Syndrome Scale (PANSS) e a widely used
instrument (Foussias and Remington, 2010) e could increase the
construct validity. The PANSS and the SANS have a considerable
overlap in how they measure symptoms, but the speciﬁc set of
symptoms they measure differs (Lyne et al., 2012; Rabany et al.,
2011), which makes the PANSS an interesting addition to factor
analysis ﬁndings on the SANS. In addition, most previous factor
analyses were performed on relatively small samples (n< 200) and
only on patients with a diagnosis of schizophrenia and substantially
evident negative symptoms.
The aim of this study is to examine the negative symptom
structure and its resemblance to the model proposed by the DSM-V
while taking care of aforementioned limitations of earlier studies.
Therefore, we investigated negative symptom structure in large,
unbiased (i.e. not selected for a certain research purpose) groups of
patients with a broad range of psychotic disorders using the PANSS
to validate ﬁndings on the SANS. We focus on PANSS items already
related to negative symptoms. Exploratory factor analysis (EFA) will
be applied to reveal the underlying structure of the symptoms, and
conﬁrmatory factor analysis (CFA) will be performed in a separate,
large sample to determine the robustness of the factor structure
(Blanchard and Cohen, 2006).2. Methods
2.1. Study samples
All data used in this study were handled anonymously, and all
subjects gave oral and written informed consent. Research was
carried out in accordance with the latest version of the Declaration
of Helsinki and approved by the local ethical committee. Most
patients in the study samples were outpatient, recently diagnosed
with a psychotic disorder (American Psychiatric Association, 2000).
A deﬁnite diagnosis could not always been given at this point,
because of the often short duration of illness.
For the EFA, a cohort of 664 cases from the province of Gro-
ningen (Early Psychosis Outcome Groningen, EPOG), the
Netherlands, was used. These patients followed a clinical assess-
ment for diagnostic purposes at the department of psychotic
disorders in the University Center Psychiatry in Groningen (1998e
2009). All patients had a diagnosis in the psychotic spectrum ac-
cording to DSM-IV diagnostic criteria.
For the CFA, we used an independent sample of 2172 cases,
comprising three subsamples. The ﬁrst group comprised a nation-
wide, longitudinal study: Genetic Risk and Outcome of Psychosis
(GROUP) of persons aged 18e50 years, Dutch speaking and on
stable antipsychotic treatment (>1 month) (2004e2007). They all
had a diagnosis of non-affective psychotic disorder (schizophrenia,
schizophreniform disorder, schizoaffective disorder, delusional
disorder, psychotic disorder NOS; DSM-IV). The second group
consisted of subjects with a ﬁrst episode of psychosis and treated at
the Academic Medical Centre, Amsterdam (2006e2010). The third
group was a cohort from the University Medical Center Utrecht, the
Netherlands, who underwent a PANSS interview for clinical or
research purposes (2006e2011).
The demographic variables are presented per cohort to provide
a general overview of the samples (Table 1). Given that the data
were collected for diagnostic purposes in the ﬁrst place, not all
demographic information was fully available. Diagnoses were
combined in categories for overview (the category psychotic dis-
orders included psychotic disorder NOS, brief psychotic disorder,
and delusional disorder). Age and PANSS scores (not normally
distributed) were tested with a Kruskal Wallis test between all
samples and with a ManneWhitney U test between the EFA and
CFA cohorts. Gender and primary diagnosis were tested with a Chi-
squared test for independence both between all samples and the
EFA and CFA samples.
2.2. Study design
The PANSS is a diagnostic interview with three parts: Positive
symptoms (7 items), Negative symptoms (7 items) and General
pathology (16 items) (Kay et al., 1987). The interviews were
administered by experienced raters who had, at minimum,
participated in an annual consensus training (inter-rater
reliability > 0.8).
We choose to do a data-driven, non-biased selection of items
that reﬂect negative symptoms in the PANSS. To accomplish this,
we selected items that had been identiﬁed as negative symptoms in
factor analyses of the whole PANSS, and that also showed a mod-
erate correlation with other negative symptoms (For correlation
matrix see Supplementary material). To identify items of previous
factor analyses, a literature search was conducted in PubMed using
the search terms: “factor analysis OR factor structure AND PANSS”.
All retrieved studies were searched for cross-references: 33 studies
that reported on a negative symptom factor in the PANSS were
identiﬁed (Bell et al., 1992, 1994; Davis and Chen, 2001; Dollfus and
Petit, 1995a,b; Drake et al., 2003; Emsley et al., 2003; Fitzgerald
Table 1
Overview of the cohorts’ demographic data; the EPOG cohort was used for the exploratory factor analysis (EFA), the GROUP cohort and the Utrecht (UTR) and Amsterdam
(AMS) cohorts were combined for the conﬁrmatory factor analysis (CFA); ‘e’ indicates datawas not available, some percentages do not reach 100% because only part of the data
was available for these categories; ‘X’ indicates that a category was not present for that particular dataset.
EFA CFA
EPOG GROUP AMS UTR
N ¼ 664 N ¼ 1288 N ¼ 375 N ¼ 658
Age Mean (SD) 27.7 (8.9) 27.7 (8.1) 21.7 (5.5) 32.0 (9.8)
Gender (% Male) 73 76 78 60
Highest education level Primary school 18 12 2 1
Special education x 12 2 7
Secondary school (low levels) 28 19 31 7
High school 20 24 20 10
Vocational education 18 17 21 19
Vocational education (high) 8 9 8 17
University 5 4 11 1
None 1 1 x 2
Maritial status (%) Not married 90 82 e 42
Married 5 9 e 14
Divorced 4 3 e 1
Household (%) Independent alone 38 31 e x
With parent(s) 34 36 e 39
With partner/family 12 9 e 79
Mental health institute 3 9 e 40
Other 12 6 e x
Primary diagnosis (%) Schizophrenia 42 65 52 24
Schizoaffective 5 11 10 2
Schizophreniform 8 6 10 2
Psychotic disorder 20 14 16 4
Substance abuse 6 1 4 1
Depression/bipolar 9 2 5 9
Other 7 2 3 34
Employment (%) Employed 45 53 58 31
Unemployed 30 24 28 7
Student 16 37 x 16
Other 7 x x 1
Antipsychotic (%) None/not applicable 19 11 e x
Risperidone 29 18 e 4
Olanzapine 28 22 e 10
Quetiapine 4 5 e 3
Clozapine 1 8 e 5
Aripiprazol 2 6 e 2
Strong DA-antagonist 16 10 e 3
PANSS total Mean (SD) 56.7 (12.6) 56.7 (16.1) 65.5 (20.3) 48.0 (18.9)
PANSS Positive Mean (SD) 12.6 (4.8) 12.6 (4.8) 16.2 (6.7) 11.8 (5.7)
PANSS Negative Mean (SD) 14.3 (6.0) 14.3 (6.0) 16.0 (6.7) 12.1 (6.1)
PANSS General Mean (SD) 29.7 (8.1) 30.0 (8.1) 33.3 (10.5) 24.3 (8.9)
E. Liemburg et al. / Journal of Psychiatric Research 47 (2013) 718e725720et al., 2003; Fredrikson et al., 1997; Fresan et al., 2005; Higashima
et al., 1998; Kawasaki et al., 1994; Kay and Sevy, 1990; Lancon
et al., 1998, 1999, 2000; Lee et al., 2003; Lindenmayer et al.,
1994a,b, Lindenmayer et al., 2004; Lindström and Von Knorring,
1993; Loas et al., 1997; Lykouras et al., 2000; Lépine et al., 1989;
Mass et al., 2000; Rapado-Castro et al., 2010; Reichenberg et al.,
2005; Van der Gaag et al., 2006a; Vilaplana et al., 2007; White
et al., 1997; Wolthaus et al., 2000). See Supplementary material.
PANSS items N5 Abstract thinking and N7 Stereotyped thinking
from the original negative subscale of the PANSS, were seldom
(both 3 times) reported as a negative symptom by these factor
analyses and showed a correlation of <0.3 to the other negative
symptoms, and were therefore not considered further in our
analysis.
Further selection was based on correlations of N1, N2, N3, N4 or
N6 with other PANSS items. A factor analysis requires items to have
a moderate, positive inter-correlation (Stevens, 1996; Tabachnik
and Fidell, 2007). A correlation matrix with Spearman’s correla-
tions of all items from the EPOG-database was created. Items
showing a correlation of >0.3 for at least three times with N1, N2,
N3, N4 or N6 were selected for further analysis. Based on the above
criteria, the following were selected for factor analysis: N1 Flataffect, N2 Emotional withdrawal, N3 Poor rapport, N4 Passive/
apathetic social withdrawal, N6 Lack of spontaneity, G5 Manner-
isms and posturing, G7 Motor retardation, G13 Avolition, and G16
Active social avoidance.2.3. Exploratory factor analysis
Items selected according to the above criteria were entered into
an EFA (Principal Axis Factoring) using Statistical Package for Social
Sciences (SPSS 16). The factor analysis was based on the correlation
matrix of the items. The KaisereMeyereOklin (KMO) and Bartlett’s
test for sphericity were calculated. The number of factors was not
ﬁxed beforehand, but factors were only retainedwhen they showed
an eigenvalue of>1. Itemswithin a factor were only retained with a
factor loading of >0.3. After factor estimation, both Direct Oblimin
rotation with Kaiser Normalization and Varimax was applied. The
Oblimin solution was reported because we expected the factors to
be correlated (r > 0.32) (Tabachnik and Fidell, 2007). The Varimax
solution was reported for completeness, because Varimax is com-
mon practice in the ﬁeld. Results can now be compared to other
studies reporting the Varimax solution.
Table 2
Factor structure of factor analysis on items N1, N2, N3, N4, N6, G5, G7, G13 and G16 of
the PANSS after Varimax rotation; Bold values indicate that the item loaded stron-
gest on this factor.
Factor 1 Factor 2
Unrotated
loading
Rotated
loading
Unrotated
loading
Rotated
loading
N6 Lack of spontaneity 0.756 0.807 0.357 0.202
N3 Poor rapport 0.744 0.759 0.297 0.257
N1 Flat affect 0.713 0.594 0.080 0.403
G7 Motor retardation 0.645 0.571 0.124 0.325
G5 Mannerisms and posturing 0.443 0.460 0.189 0.144
G13 Avolition 0.435 0.406 0.117 0.194
N4 Passive/apathetic
social withdrawal
0.807 0.287 L0.503 0.906
N2 Emotional withdrawal 0.777 0.386 L0.315 0.744
G16 Active social avoidance 0.431 0.158 L0.261 0.478
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We then performed a CFA in LISREL 8 (Jöreskog and Sörbom,
2011) to investigate the ﬁt of the model identiﬁed by EFA. Because
of non-normality, an asymptotic covariance matrix was used for
estimation and comparative ﬁt indices were used instead of the
traditional Chi-square values (Hu and Bentler, 1998; Lei and Lomax,
2005; Powel and Schafer, 2001; Yuan and Bentler, 1998). The factors
identiﬁed by EFAwere entered as latent variables in the CFA and the
PANSS items were entered as observed variables. The maximum
likelihood method was used for estimation (Van der Gaag et al.,
2006a). We used multiple indices to measure goodness-of-ﬁt: the
Comparative Fit Index (CFI > 0.9), the Goodness-of-Fit index
(GFI > 0.9), the Root Mean Square Error of Approximation
(RMSEA < 0.06), the Root Mean Square of Residuals (RMR < 0.05),
and an unstandardized factor loading >2 * standardized factor
loading (Albright and Park, 2009; Hu and Bentler,1998;Marsch et al.,
2004). Correlated measurement errors were introduced into the
model based on signiﬁcantly correlated residuals indicated by
modiﬁcation indices. Improvement of the model and the impact of
correlated measurement errors were assessed in this way.
Many factor analyses on the PANSS focused on schizophrenia,
while our focus was on psychotic disorders. To investigate whether
this broader diagnostic inclusion of diagnoses compared to other
studies affected the structure of symptoms, the CFA was repeated
with patients with a DSM-IV diagnosis of schizophrenia from the
GROUP database. Moreover, the severity of symptoms was rela-
tively low, which may have an inﬂuence on the factor structure.
Therefore, analysis was also repeated in 50% of the sample showing
the highest summed score on the selected negative symptoms.
Correlated residuals were also introduced in both CFA models,
similar to the model with all diagnoses and all cases included. The
goodness-of-ﬁt measures of both were compared to the original
models, both with and without correlated residuals.
To test the validity of the factor structure, summed scores on both
factors were non-parametrically correlated with neuropsychological
and clinical measures of the GROUP database. We included the
Community Assessment of Psychotic Experiences (CAPE; rating self-
reports of lifetime psychotic experiences; Konings et al., 2006),
Schedule for the Deﬁcit Syndrome (SDS; categorizing patients into
deﬁcit or non-deﬁcit subgroups; Kirkpatrick et al., 1989), Structured
Interview for Schizotypy-Revised (SIS-R; semi-structured interview
assessing schizotypal symptoms; Kendler et al., 1989; Vollema and
Ormel, 2000), WAIS III (neuropsychological test; Wechsler, 1997),
Camberwell Assessment scale of Need Short Appraisal Schedule
(CANSAS; Slade et al., 1999), and the World Health Organization
Quality of Life (Trompenaars et al., 2005). The SDS was of speciﬁc
interest, as our factors may in some way be related to deﬁcit syn-
drome. Qualitative (descriptive) differences in strength of non-
parametric association between different PANSS factors were
assessed.
3. Results
First, socio-demographic data of the cohorts were inspected and
the EFA and CFA groups were compared (Table 1). The age of the
subjects rangedmostly between 20 and 30 years, and 60e78%were
male. Most subjects had a primary diagnosis of schizophrenia or a
psychotic disorder. Around 10% of the subjects had another diag-
nosis, but these subjects had at least a differential diagnosis or
comorbid diagnosis within the psychotic spectrum, which is not
reported. Subjects from the Amsterdam cohort were generally
younger and subjects from the Utrecht cohort had lower PANSS
scores. All cohorts when tested separately showed a signiﬁcant
difference in age (p< 0.0005), but the comparison between the EFAand CFA samples did not (p ¼ 0.20). Gender (p ¼ 1) and diagnosis
(p¼ 0.23) were not signiﬁcantly different between the EFA and CFA
sample, whereas they were signiﬁcantly different in the compari-
son between all four samples separately (p < 0.0005). As the CFA
sample was used in all analyses, non-signiﬁcant differences in age,
gender, and diagnosis between those two samples were considered
most relevant for interpretation of the data. PANSS original sub-
scales (Positive symptoms, Negative symptoms and General Pa-
thology), deﬁned by Kay et al. (1987) were signiﬁcantly different
between all samples (all p < 0.005), but the differences were not
regarded as clinically relevant (only one point difference in mean
between samples).
3.1. Exploratory factor analysis
Inspection of a histogram of the data and a QeQ plot showed a
non-normal, left-skewed distribution. Factor analysis on EPOG
(n ¼ 644) resulted in a KaisereMeyereOklin (KMO) of 0.85
(excellent) and a signiﬁcant result for the Bartlett’s test for sphe-
ricity (Chi ¼ 2598.9; p < 0.005), indicating that the correlation
matrix was suitable for factor analysis. A two-factor solution indi-
cated an eigenvalue >1 (60% of the variance explained) with all
factor loadings above 0.3. Communalities were all above 0.3, indi-
cating that all items explained a substantial amount of variance.
The two factors had a strong, negative correlation of 0.64, indi-
cating the Oblimin solution should be reported (>0.32, according to
Tabachnik and Fidell, 2007). The Varimax solution (Table 2) showed
that, after rotation, items loaded preferably either on Factor 1 or
Factor 2. The Oblimin rotation (Table 3) resulted in one factor with
items loading the strongest in the positive direction, while Factor 2
items loaded the strongest in the negative direction.
3.2. Conﬁrmatory factor analysis
The CFA was based on a merged sample of three databases
(GROUP, Amsterdam, Utrecht) of 2172 cases. A model was created
based on the results of the EFA (Fig. 1). The CFA by LISREL indicated
a moderate ﬁt if correlated residuals were not introduced into the
model. The following goodness-of-ﬁt indices were obtained (with
criteria for a good ﬁt given in brackets): CFI ¼ 0.99 (>0.9),
GFI ¼ 0.99 (>0.9), RMSEA ¼ 0.063 (<0.06), RMR ¼ 0.071 (<0.05),
and unstandardized factor loading/standardized factor loading >2
(>2). Next, signiﬁcantly correlated residuals (measurement errors)
were introduced into the model to improve the ﬁt (Cole et al., 2011;
Gerbing and Anderson, 1984), see Fig. 1. This model resulted in the
following ﬁt: CFI ¼ 1.0 (>0.9), GFI ¼ 1.0 (>0.9), RMSEA ¼ 0.015
(<0.06), RMR ¼ 0.015 (<0.05), and unstandardized factor loading/
Table 3
Factor structure of factor analysis on items N1, N2, N3, N4, N6, G5, G7, G13 and G16 of
the PANSS after Oblimin rotation; the unrotated solutions are identical to the
unrotated Varimax solution; Bold values indicate that the item loaded strongest on
this factor.
Factor 1 Factor 2
Pattern
coefﬁcient
Structure
coefﬁcient
Pattern
coefﬁcient
Structure
coefﬁcient
N6 Lack of spontaneity 0.896 0.833 0.099 0.472
N3 Poor rapport 0.822 0.801 0.033 0.491
N1 Flat affect 0.577 0.697 0.219 0.575
G7 Motor retardation 0.563 0.649 0.135 0.494
G5 Mannerisms and
posturing
0.503 0.481 0.034 0.286
G13 Avolition 0.416 0.449 0.510 0.316
N4 Passive/apathetic
social withdrawal
0.033 0.586 L0.971 L0.950
N2 Emotional withdrawal 0.158 0.623 L0.729 L0.830
G16 Active social avoidance 0.10 0.315 L0.510 L0.504
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ﬁt of the model when correlated residuals were introduced.
The CFA was repeated in a sample of 845 cases with a DSM-IV
diagnosis of schizophrenia from the GROUP database. The following
goodness-of-ﬁt indices were obtained in the model without intro-
duced correlated residuals: CFI ¼ 0.98, GFI ¼ 0.99, RMSEA ¼ 0.070,
RMR ¼ 0.079. In the model with correlated residuals the following
values were obtained: CFI ¼ 1.0, GFI ¼ 1.0, RMSEA ¼ 0.0082,
RMR¼0.019.Analysis on50%of the samplewith thehighest summed
negative symptoms gave the followingmodel ﬁts without correlated
residuals: CFI¼ 0.95, GFI¼ 0.98, RMSEA¼ 0.087, RMR¼ 0.062.With
correlated residuals the following ﬁts were obtained: CFI ¼ 0.98,
GFI¼ 0.99, RMSEA¼ 0.052, RMR¼ 0.038. The CFA analyses with the
schizophrenia group showed similar results to the analyses on the
whole sample, both with and without correlated residuals. The
analysis on symptom severity showed marginally higher values, but
still within the thresholds indicating a good model ﬁt.
Both factors showed a moderate to strong correlation with the
SDS. Interestingly, we observed a stronger correlation of the non-
social items with our Factor 1, and a stronger association between
social SDS items and Factor 2. With lower correlations, a similar
pattern was observed for the CANSAS. The CAPE and SIS-R showedFig. 1. The factor model created for the conﬁrmatory factor analysis (CFA) based on the resul
the boxes on the right indicate the PANSS items connected to their corresponding factor by a
introduced into the model. Values on top of the arrows indicate the factor loadings. Each ismall to moderate correlations with both factors (0.1e0.4), but al-
ways slightly stronger for Factor 2. The WAIS showed a negative
correlation with both factors, but now minutely stronger with
Factor 1. Quality of life (QoL) was also lower for patients with higher
scores of both factors, but the effect of Factor 2 was stronger.4. Discussion
We found that a two-factor model represents negative symp-
toms better than a single factor, albeit that the two factors are
correlated. We conﬁrmed this two-factor model by CFA in a sepa-
rate cohort and demonstrated that the model is not restricted to a
diagnosis of schizophrenia or to higher symptom severity, but also
ﬁts for psychotic disorders with milder levels of symptoms. The
ﬁrst factor of the model comprises items that show similarity to the
“expressive deﬁcits” domain of DSM-V, with the highest factor
loadings on Flat affect (N1), Poor rapport (N3), and Lack of spon-
taneity (N6). In the second factor, the items resembled aspects of
the “social amotivation” domain of DSM-V, with the highest load-
ings on Emotional withdrawal (N2) and Passive/apathetic social
withdrawal (N4).
Our two-dimension structure of negative symptoms provided
good support for the twonegative symptomdomainsproposed in the
DSM-V (Messinger et al., 2011) and agrees with earlier proposed
symptom models (Keefe et al., 1992; Kirkpatrick et al., 2001). More-
over, the two-factor division determined by PANSS robustly extends
the results of other studies suggesting two negative symptom do-
mains that were mainly based on SANS (Bell et al., 2011; Blanchard
and Cohen, 2006; Foussias and Remington, 2010,Keefe et al., 1992;
Kimhy et al., 2006; Kirkpatrick and Fischer, 2006; Lindström and Von
Knorring, 1993; Messinger et al., 2011; Peralta and Cuesta, 1995; Van
den Oord et al., 2006).
Of note, Avolition (G13) and Flat affect (N1) would conceptually
also ﬁt Factor 2, social avolition/amotivation. Indeed, the items
loaded relatively strong on both factors. We removed both items
from the EFA separately to investigate the effects on factor struc-
ture. But as this did not change the factor structure of the other
items, we retained both items in the model. Factor analysis is a
data-driven method, and multiple aspects may inﬂuence the factor
loading of items. While Flat Affect (N1) and Avolition (G13)ts of the exploratory factor analysis (EFA). The two boxes on the left indicate our factors,
rrows, and the arrows connecting the right-hand boxes indicate the correlated residuals
tem also has its own error term, but these are not shown for simplicity.
E. Liemburg et al. / Journal of Psychiatric Research 47 (2013) 718e725 723measure social communicative deﬁcits and amotivation, the rating
of these PANSS items is merely based on observed behavior.
Therefore, the items may be rated as disturbance in willful initia-
tion of behavior or facial expression, and also load the “expressive
behavior factor”.
For the negative symptom model as identiﬁed in our study, the
CFA showed a low loading or poor ﬁt of PANSS item Mannerisms
and posturing (G5). Possibly because this item in general does not
receive a high score in ratings and provides a limited amount of
variance. But as excluding it did not improve the CFA ﬁt and the
item showed a loading of >0.4 in the EFA, we retained the item in
the model. In the DSM-V, this itemwould probably ﬁt better in the
abnormal psychomotor behavior. In addition, theMotor retardation
(G7) and Avolition (G13) items also loaded lower on Factor 1,
possibly because they originate from the General Pathology sub-
scale of the PANSS.
The ﬁt of the CFA improved when we added a correction for
measurement errors to the model. An explanation could be that,
although the interviewers were well-trained, some PANSS items
may have a common origin that is difﬁcult to disentangle and thus
rated in multiple items (Cole et al., 2007; Gerbing and Anderson,
1984), e.g. reduced movement could be rated as Flat affect (N1),
Mannerism and posturing (G5), or Motor retardation (G7).
Some authors have speculated that the “expressive deﬁcits” fac-
tor may reﬂect directly apparent symptoms that change quickly over
time,while the “social amotivation” factor reﬂects the status of social
relationships that may change more slowly (Blanchard and Cohen,
2006; Foussias and Remington, 2010; Keefe et al., 1992). Moreover,
the ﬁrst group of symptoms is rated as directly observed behavior,
while the social items are based on reports from family members
and nursing staff (Messinger et al., 2011). Indeed, directly observed
behaviore Poor rapport and Lack of spontaneitye show the highest
loading on Factor 1 and thus have the strongest impact in this factor.
“Social amotivation” may be due to a diminished capacity of
patients to anticipate pleasurable events, despite intact hedonic
consumption (Foussias and Remington, 2010; Oorschot et al., 2011).
This explanation ﬁnds support in the strong loading of emotional
and apathetic withdrawal. Moreover, the “social amotivation fac-
tor” could, besides interest, also include aspects of social perfor-
mance, based on engagement in social situations (Keefe et al., 1992;
Oorschot et al., 2011).
When correlating our factor structure with clinical and psy-
chological measures, we observed a subtle but very stable differ-
ence in correlations of both factors with othermeasures. The results
suggested that both factors relate equality to deﬁcit syndrome, but
that “Expressive deﬁcits” relate stronger to non-social items, and
“Social amotivation” to social items. A similar structure of a social
and non-social symptom group in the SDS has been reported pre-
viously (Kimy et al., 2006).
Moreover, “Expressive deﬁcits” had a stronger association with
neuropsychological function, while “Social amotivation” had a
stronger association with self-reported symptoms and quality of
life. In the past, a distinction has also been made between neuro-
cognition and social cognition. Possibly, the “Expressive deﬁcits”
factor is more closely related to neurocognitive impairments, while
social cognition and the “Social amotivation” constitute a separate
domain (Bell et al., 2011; Foussias and Remington, 2010). Further-
more, social function may relate more strongly to quality of life
than other negative symptoms captured in our Factor 1, as shown
previously (Bell et al., 2011).
On a different note, Marder et al. (1997) showed in an EFA that
factor loadings on all three items of our Factor 2 had the largest
differential effect in response to haloperidol versus risperidone
treatment. Van Oord et al. (2006) found a similar distinction in
negative symptom structure as we do, and concluded that currentuse of atypical medication could make the two factors can be dis-
cerned now, whereas (high dosage) classic antipsychotics in the
past may have obscured the two subdomains.
Negative symptoms and depressive symptoms are often
considered to be associated (Fitzgerald et al., 2002; Lako et al.,
2012). Additional analysis in this study showed no association be-
tween depression and negative symptoms (results not shown),
while previous factor analyses also showed no loading of Depres-
sion (G6) on the negative symptom factors. Thus, the “expressive
deﬁcits” factor may be more a reﬂection of apathy than of
depression. Research using scales speciﬁcally designed for assess-
ing apathy (Clarke et al., 2011) or depression (Lako et al., 2012)
could further corroborate this.
A unique strength of our study is its large sample size and its
replication in large, independent cohorts. CFA is a complicated
procedure and depends strongly on the underlying data structure
(Van der Gaag et al., 2006a), thus our conﬁrmation of the negative
symptom structure can be considered quite robust. In addition, this
study is the ﬁrst to replicate ﬁndings of studies on the SANS by
using the PANSS. This is a useful addition, as the PANSS is more
frequently used in research settings and clinical practice, and it also
covers a broader range of symptoms (Fitzgerald et al., 2001; Van
den Oord et al., 2006). Of note, we reported both Varimax and
Oblimin rotation solutions. Whereas Oblimin is more valid given
the correlation between both factors, Varimax is often used and
therefore reported to enable comparison with other studies.
Some limitations should also be mentioned. The two-factor
structure may be an artifact, because the ﬁrst factor includes
symptoms rated by the interviewer during the interview, while the
second factor includes social activities outside the interview room
(Blanchard and Cohen, 2006). In this study, patients were relatively
young and often in the early stages of their illness, with only 25%
suffering from more severe negative symptoms (PANSS items > 3).
This limits our ability to draw conclusions about symptom di-
mensions in, for example, chronically ill samples. Lastly, the two
factors show a considerable association with each other and may
partly overlap. But because of the extensive support from earlier
ﬁndings, the two factors have good construct validity.
In conclusion, our results support the two subdomains proposed
in the DSM-V. The ﬁrst subdomain is related to the “expressive
deﬁcits”, while the second could be described as a “social amoti-
vation” factor. Negative symptoms are difﬁcult to treat and the
pathophysiology remains poorly understood. By acknowledging
the two dimensions that have now emerged robustly from the
factor structure of systematic assessments, the effects of in-
terventions may be assessed with greater precision (Kirkpatrick
and Fischer, 2006; Blanchard and Cohen, 2006). Research into
their differential pathophysiology, e.g. using neuroimaging, could
advance our understanding of these debilitating symptoms further
(Bell et al., 2011).
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